XK469 (2-[4-(7-chloro-2-quinoxalinyloxy) phenoxy]propionic acid), a synthetic quinoxaline phenoxypropionic acid derivative, has broad activity against murine tumors and is entering Phase I clinical development as a topoisomerase IIbeta inhibitor. This study investigated the underlying molecular mechanism of XK469's effects on the cell cycle.
Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Prentis Building, 110 East Warren, Detroit, MI 48201, USA.
